Skip to main content

Articles

Page 12 of 33

  1. Neuroleukin (NLK) is a protein with neurotrophic properties and is present in a proportion of senile plaques and amyloid laden vessels. It has been suggested that NLK is part of a neuroprotective response to a...

    Authors: Anna M. De Kort, H. Bea Kuiperij, Daniel Alcolea, Iris Kersten, Alexandra A. M. Versleijen, Steven M. Greenberg, Erik Stoops, Floris H. B. M. Schreuder, Catharina J. M. Klijn, Alberto Lleó, Jurgen A. H. R. Claassen and Marcel M. Verbeek
    Citation: Alzheimer's Research & Therapy 2021 13:160
    Content type: Research Published on:

    The Correction to this article has been published in Alzheimer's Research & Therapy 2021 13:189

  2. The brainstem locus coeruleus (LC) constitutes the intersection of the initial pathophysiological processes of Alzheimer’s disease (AD) and sleep-wake dysregulation in the preclinical stages of the disease. Ho...

    Authors: Maxime Van Egroo, Roy W. E. van Hooren and Heidi I. L. Jacobs
    Citation: Alzheimer's Research & Therapy 2021 13:159
    Content type: Research Published on:

  3. Observational studies have suggested that herpesvirus infection increased the risk of Alzheimer’s disease (AD), but it is unclear whether the association is causal. The aim of the present study is to evaluate ...

    Authors: Shu-Yi Huang, Yu-Xiang Yang, Kevin Kuo, Hong-Qi Li, Xue-Ning Shen, Shi-Dong Chen, Mei Cui, Lan Tan, Qiang Dong and Jin-Tai Yu
    Citation: Alzheimer's Research & Therapy 2021 13:158
    Content type: Research Published on:

  4. Preventive interventions for dementia are urgently needed and must be tested in randomised controlled trials (RCTs). Selection (volunteer) bias may limit efficacy, particularly in trials testing multidomain in...

    Authors: Nicola Coley, Delphine Coniasse-Brioude, Valérie Igier, Tristan Fournier, Jean-Pierre Poulain and Sandrine Andrieu
    Citation: Alzheimer's Research & Therapy 2021 13:157
    Content type: Research Published on:

  6. For the recruitment and monitoring of subjects for therapy studies, it is important to predict whether mild cognitive impaired (MCI) subjects will prospectively develop Alzheimer’s disease (AD). Machine learni...

    Authors: Louise Bloch and Christoph M. Friedrich
    Citation: Alzheimer's Research & Therapy 2021 13:155
    Content type: Research Published on:

  7. Alzheimer’s disease is the most common cause of dementia, and currently, there is no disease-modifying treatment. Favorable functional outcomes and reduction of amyloid levels were observed following transplan...

    Authors: Hee Jin Kim, Kyung Rae Cho, Hyemin Jang, Na Kyung Lee, Young Hee Jung, Jun Pyo Kim, Jung Il Lee, Jong Wook Chang, Seongbeom Park, Sung Tae Kim, Seung Whan Moon, Sang Won Seo, Soo Jin Choi and Duk L. Na
    Citation: Alzheimer's Research & Therapy 2021 13:154
    Content type: Research Published on:

  8. Comprehensive testing of cognitive functioning is standard practice in studies of Alzheimer disease (AD). Short-form tests like the Montreal Cognitive Assessment (MoCA) use a “sampling” of measures, administer...

    Authors: Jason Hassenstab, Jessica Nicosia, Megan LaRose, Andrew J. Aschenbrenner, Brian A. Gordon, Tammie L. S. Benzinger, Chengjie Xiong and John C. Morris
    Citation: Alzheimer's Research & Therapy 2021 13:153
    Content type: Research Published on:

  9. Although educational interventions are recommended in Alzheimer’s disease (AD), studies assessing the impact of interventions such as “therapeutic patient education” are scarce. Indeed, the intrinsic nature of...

    Authors: Hélène Villars, Christelle Cantet, Eva de Peretti, Amelie Perrin, Maria Soto-martin and Virginie Gardette
    Citation: Alzheimer's Research & Therapy 2021 13:152
    Content type: Research Published on:

  10. In Alzheimer’s disease, amyloid- β (A β) peptides aggregate in the lowering CSF amyloid levels - a key pathological hallmark of the disease. However, lowered CSF amyloid levels may also be present in cognitively ...

    Authors: Hákon Valur Dansson, Lena Stempfle, Hildur Egilsdóttir, Alexander Schliep, Erik Portelius, Kaj Blennow, Henrik Zetterberg and Fredrik D. Johansson
    Citation: Alzheimer's Research & Therapy 2021 13:151
    Content type: Research Published on:

  11. Aging is associated with declining protective immunity and persistent low-grade inflammatory responses, which significantly contribute to Alzheimer’s disease (AD) pathogenesis. Detecting aging-related cerebral...

    Authors: Lucia Reseco, Mercedes Atienza, Marina Fernandez-Alvarez, Eva Carro and Jose L. Cantero
    Citation: Alzheimer's Research & Therapy 2021 13:150
    Content type: Research Published on:

  12. Alzheimer’s disease, cardiovascular disease, and other cardiometabolic disorders may share inflammatory origins. Lipid mediators, including oxylipins, endocannabinoids, bile acids, and steroids, regulate infla...

    Authors: Kamil Borkowski, Theresa L. Pedersen, Nicholas T. Seyfried, James J. Lah, Allan I. Levey, Chadwick M. Hales, Eric B. Dammer, Colette Blach, Gregory Louie, Rima Kaddurah-Daouk and John W. Newman
    Citation: Alzheimer's Research & Therapy 2021 13:149
    Content type: Research Published on:

  13. Thoroughly understanding the temporal associations between cognitive and functional dimensions along the dementia process is fundamental to define preventive measures likely to delay the disease’s onset. This ...

    Authors: Sophie Carles, Bachirou O. Taddé, Claudine Berr, Catherine Helmer, Hélène Jacqmin-Gadda, Isabelle Carrière and Cécile Proust-Lima
    Citation: Alzheimer's Research & Therapy 2021 13:148
    Content type: Research Published on:

  14. Leukotriene receptor antagonists (LTRAs) alleviate Alzheimer’s disease (AD) pathology and improve cognition in animal models; however, clinical evidence is limited. This study aimed to explore the associations...

    Authors: Lisa Y. Xiong, Michael Ouk, Che-Yuan Wu, Jennifer S. Rabin, Krista L. Lanctôt, Nathan Herrmann, Sandra E. Black, Jodi D. Edwards and Walter Swardfager
    Citation: Alzheimer's Research & Therapy 2021 13:147
    Content type: Research Published on:

  15. Identification of reliable, affordable, and easy-to-use strategies for detection of dementia is sorely needed. Digital technologies, such as individual voice recordings, offer an attractive modality to assess ...

    Authors: Chonghua Xue, Cody Karjadi, Ioannis Ch. Paschalidis, Rhoda Au and Vijaya B. Kolachalama
    Citation: Alzheimer's Research & Therapy 2021 13:146
    Content type: Research Published on:

  16. To understand the potential for early intervention and prevention measures in Alzheimer’s disease, the association between risk factors and early pathological change needs to be assessed. Hence, the aim of thi...

    Authors: Tobias Möllers, Hannah Stocker, Laura Perna, Andreas Nabers, Dan Rujescu, Annette M. Hartmann, Bernd Holleczek, Ben Schöttker, Klaus Gerwert and Hermann Brenner
    Citation: Alzheimer's Research & Therapy 2021 13:145
    Content type: Research Published on:

  17. Epidemiological studies link vascular disease risk factors such as atherosclerosis, hypertension, and diabetes mellitus with Alzheimer’s disease (AD). Whether there are direct links between these conditions to...

    Authors: Min Wang, Junyan Lv, Xiaoshan Huang, Thomas Wisniewski and Wei Zhang
    Citation: Alzheimer's Research & Therapy 2021 13:144
    Content type: Research Published on:

  18. While still controversial, it has been demonstrated that vascular defects can precede the onset of other AD hallmarks features, making it an important therapeutic target. Given that the protein transthyretin (...

    Authors: Tiago Gião, Joana Saavedra, José Ricardo Vieira, Marta Teixeira Pinto, Gemma Arsequell and Isabel Cardoso
    Citation: Alzheimer's Research & Therapy 2021 13:143
    Content type: Research Published on:

  19. Varoglutamstat (formerly PQ912) is a small molecule that inhibits the activity of the glutaminyl cyclase to reduce the level of pyroglutamate-A-beta (pGluAB42). Recent studies confirm that pGluAB42 is a partic...

    Authors: E. G. B. Vijverberg, T. M. Axelsen, A. R. Bihlet, K. Henriksen, F. Weber, K. Fuchs, J. E. Harrison, K. Kühn-Wache, P. Alexandersen, N. D. Prins and Philip Scheltens
    Citation: Alzheimer's Research & Therapy 2021 13:142
    Content type: Research Published on:

  20. To explore whether the combination of white matter hyperintensities (WMHs) and amyloid-beta (Aβ) deposition is associated with worse cognitive performance on cognitive composites (CCs) domain scores in individ...

    Authors: G. Ortega, A. Espinosa, M. Alegret, GC. Monté-Rubio, O. Sotolongo-Grau, A. Sanabria, JP. Tartari, O. Rodríguez-Gómez, M. Marquié, A. Vivas, M. Gómez-Chiari, E. Alarcón-Martín, A. Pérez-Cordón, N. Roberto, I. Hernández, M. Rosende-Roca…
    Citation: Alzheimer's Research & Therapy 2021 13:141
    Content type: Research Published on:

  21. Alzheimer’s disease, among other neurodegenerative disorders, spans decades in individuals’ life and exhibits complex progression, symptoms and pathophysiology. Early diagnosis is essential for disease prevent...

    Authors: Valentina Escott-Price and Karl Michael Schmidt
    Citation: Alzheimer's Research & Therapy 2021 13:140
    Content type: Research Published on:

    The Correction to this article has been published in Alzheimer's Research & Therapy 2021 13:156

  22. Entrainment of neural oscillations in occipital cortices by external rhythmic visual stimuli has been proposed as a novel therapy for patients with Alzheimer’s disease (AD). Despite this increased interest in ...

    Authors: Alex I. Wiesman, Daniel L. Murman, Pamela E. May, Mikki Schantell, Sara L. Wolfson, Craig M. Johnson and Tony W. Wilson
    Citation: Alzheimer's Research & Therapy 2021 13:139
    Content type: Research Published on:

  23. Changes in grey matter covariance networks have been reported in preclinical and clinical stages of Alzheimer’s disease (AD) and have been associated with amyloid-β (Aβ) deposition and cognitive decline. Howev...

    Authors: Wiesje Pelkmans, Rik Ossenkoppele, Ellen Dicks, Olof Strandberg, Frederik Barkhof, Betty M. Tijms, Joana B. Pereira and Oskar Hansson
    Citation: Alzheimer's Research & Therapy 2021 13:138
    Content type: Research Published on:

  24. To systematically examine the clinical utility of tau-PET and Braak-staging as prognostic markers of future cognitive decline in older adults with and without cognitive impairment.

    Authors: Davina Biel, Matthias Brendel, Anna Rubinski, Katharina Buerger, Daniel Janowitz, Martin Dichgans and Nicolai Franzmeier
    Citation: Alzheimer's Research & Therapy 2021 13:137
    Content type: Research Published on:

  25. Chronic traumatic encephalopathy (CTE) is a neurodegenerative disease that has been neuropathologically diagnosed in brain donors exposed to repetitive head impacts, including boxers and American football, soc...

    Authors: Michael L. Alosco, Megan L. Mariani, Charles H. Adler, Laura J. Balcer, Charles Bernick, Rhoda Au, Sarah J. Banks, William B. Barr, Sylvain Bouix, Robert C. Cantu, Michael J. Coleman, David W. Dodick, Lindsay A. Farrer, Yonas E. Geda, Douglas I. Katz, Inga K. Koerte…
    Citation: Alzheimer's Research & Therapy 2021 13:136
    Content type: Research Published on:

  26. Perivascular spaces (PVS) have an important role in the elimination of metabolic waste from the brain. It has been hypothesized that the enlargement of PVS (ePVS) could be affected by pathophysiological mechan...

    Authors: Natalia Vilor-Tejedor, Iacopo Ciampa, Grégory Operto, Carles Falcón, Marc Suárez-Calvet, Marta Crous-Bou, Mahnaz Shekari, Eider M. Arenaza-Urquijo, Marta Milà-Alomà, Oriol Grau-Rivera, Carolina Minguillon, Gwendlyn Kollmorgen, Henrik Zetterberg, Kaj Blennow, Roderic Guigo, José Luis Molinuevo…
    Citation: Alzheimer's Research & Therapy 2021 13:135
    Content type: Research Published on:

  27. Understanding the changes that occur in the transitional stage between absent and overt amyloid-β (Aβ) pathology within the Alzheimer’s continuum is crucial to develop therapeutic and preventive strategies. The o...

    Authors: Marta Milà-Alomà, Mahnaz Shekari, Gemma Salvadó, Juan Domingo Gispert, Eider M. Arenaza-Urquijo, Grégory Operto, Carles Falcon, Natalia Vilor-Tejedor, Oriol Grau-Rivera, Aleix Sala-Vila, Gonzalo Sánchez-Benavides, José Maria González-de-Echávarri, Carolina Minguillon, Karine Fauria, Aida Niñerola-Baizán, Andrés Perissinotti…
    Citation: Alzheimer's Research & Therapy 2021 13:134
    Content type: Research Published on:

  28. We assessed the performance of plasma amyloid oligomerization tendency (OAβ) as a marker for abnormal amyloid status. Additionally, we examined long-term storage effects on plasma OAβ.

    Authors: Rosha Babapour Mofrad, Philip Scheltens, SangYun Kim, Sungmin Kang, Young Chul Youn, Seong Soo A. An, Jori Tomassen, Bart N. M. van Berckel, Pieter Jelle Visser, Wiesje M. van der Flier and Charlotte E. Teunissen
    Citation: Alzheimer's Research & Therapy 2021 13:133
    Content type: Research Published on:

  29. In the current study, we aimed to develop an algorithm based on biomarkers obtained through non- or minimally invasive procedures to identify healthy elderly subjects who have an increased risk of abnormal cer...

    Authors: Samantha Prins, Ahnjili Zhuparris, Ellen P. Hart, Robert-Jan Doll and Geert Jan Groeneveld
    Citation: Alzheimer's Research & Therapy 2021 13:132
    Content type: Research Published on:

  30. Many patients with Alzheimer’s disease (AD) are physically frail or have substantial functional impairments. There is growing evidence that such patients are at higher risk for medication-induced adverse event...

    Authors: M. Seibert, V. Mühlbauer, J. Holbrook, S. Voigt-Radloff, S. Brefka, D. Dallmeier, M. Denkinger, C. Schönfeldt-Lecuona, S. Klöppel and C. A. F. von Arnim
    Citation: Alzheimer's Research & Therapy 2021 13:131
    Content type: Research Published on:

  31. Leukocyte telomere length (LTL) has been shown to predict Alzheimer’s disease (AD), albeit inconsistently. Failing to account for the competing risks between AD, other dementia types, and mortality, can be an ...

    Authors: Fernanda Schäfer Hackenhaar, Maria Josefsson, Annelie Nordin Adolfsson, Mattias Landfors, Karolina Kauppi, Magnus Hultdin, Rolf Adolfsson, Sofie Degerman and Sara Pudas
    Citation: Alzheimer's Research & Therapy 2021 13:130
    Content type: Research Published on:

    The Correction to this article has been published in Alzheimer's Research & Therapy 2024 16:39

  32. We aimed to systematically describe the burden and distribution of white matter hyperintensities (WMH) and investigate correlations with neuropsychiatric symptoms in pathologically proven Alzheimer’s disease (...

    Authors: Philippe Desmarais, Andrew F. Gao, Krista Lanctôt, Ekaterina Rogaeva, Joel Ramirez, Nathan Herrmann, Donald T. Stuss, Sandra E. Black, Julia Keith and Mario Masellis
    Citation: Alzheimer's Research & Therapy 2021 13:129
    Content type: Research Published on:

  33. Cognitive reserve is most commonly measured using socio-behavioural proxy variables. These variables are easy to collect, have a straightforward interpretation, and are widely associated with reduced risk of d...

    Authors: R. Boyle, S. P. Knight, C. De Looze, D. Carey, S. Scarlett, Y. Stern, I. H. Robertson, R. A. Kenny and R. Whelan
    Citation: Alzheimer's Research & Therapy 2021 13:128
    Content type: Research Published on:

  34. Although social cognitive dysfunction is a major feature of frontotemporal dementia (FTD), it has been poorly studied in familial forms. A key goal of studies is to detect early cognitive impairment using vali...

    Authors: Hannah D. Franklin, Lucy L. Russell, Georgia Peakman, Caroline V. Greaves, Martina Bocchetta, Jennifer Nicholas, Jackie Poos, Rhian S. Convery, David M. Cash, John van Swieten, Lize Jiskoot, Fermin Moreno, Raquel Sanchez-Valle, Barbara Borroni, Robert Laforce Jr, Mario Masellis…
    Citation: Alzheimer's Research & Therapy 2021 13:127
    Content type: Research Published on:

  35. Blood circulating microRNAs that are specific for Alzheimer’s disease (AD) can be identified from differentially expressed microRNAs (DEmiRNAs). However, non-reproducible and inconsistent reports of DEmiRNAs h...

    Authors: Sze Chung Yuen, Xiaonan Liang, Hongmei Zhu, Yongliang Jia and Siu-wai Leung
    Citation: Alzheimer's Research & Therapy 2021 13:126
    Content type: Research Published on:

  36. Amyloid precursor protein (APP) processing is central to Alzheimer’s disease (AD) etiology. As early cognitive alterations in AD are strongly correlated to abnormal information processing due to increasing syn...

    Authors: Maria Mensch, Jade Dunot, Sandy M. Yishan, Samuel S. Harris, Aline Blistein, Alban Avdiu, Paula A. Pousinha, Camilla Giudici, Marc Aurel Busche, Peter Jedlicka, Michael Willem and Hélène Marie
    Citation: Alzheimer's Research & Therapy 2021 13:125
    Content type: Research Published on:

  37. In 2019, the Lewy Body Dementia Association formed an Industry Advisory Council to bring together a collaborative group of stakeholders with the goal of accelerating clinical research into Lewy body dementia t...

    Authors: Jennifer G. Goldman, Bradley F. Boeve, Melissa J. Armstrong, Doug R. Galasko, James E. Galvin, David J. Irwin, James B. Leverenz, Karen Marder, Victor Abler, Kevin Biglan, Michael C. Irizarry, Bill Keller, Robert Lai, Leanne Munsie, Michael Belleville, Ondrea Chaney…
    Citation: Alzheimer's Research & Therapy 2021 13:124
    Content type: Meeting report Published on:

  38. Plasma biomarkers showed a promising value in the disease diagnosis and management of Alzheimer’s disease (AD). However, profiles of the biomarkers and the associations with cognition across a spectrum of cogn...

    Authors: Zhenxu Xiao, Xue Wu, Wanqing Wu, Jingwei Yi, Xiaoniu Liang, Saineng Ding, Li Zheng, Jianfeng Luo, Hongchen Gu, Qianhua Zhao, Hong Xu and Ding Ding
    Citation: Alzheimer's Research & Therapy 2021 13:123
    Content type: Research Published on:

  39. Genetic studies have primarily been conducted in European ancestry populations, identifying dozens of loci associated with late-onset Alzheimer’s disease (AD). However, much of AD’s heritability remains unexpl...

    Authors: Andréa R. V. R. Horimoto, Diane Xue, Timothy A. Thornton and Elizabeth E. Blue
    Citation: Alzheimer's Research & Therapy 2021 13:122
    Content type: Research Published on:

  40. Arterial stiffening has emerged as an important risk factor for Alzheimer’s disease (AD) and related dementias. Carotid-femoral pulse wave velocity has been proposed as a non-invasive and reproducible method t...

    Authors: Katherine J. Bangen, Denis S. Smirnov, Lisa Delano-Wood, Christina E. Wierenga, Mark W. Bondi, David P. Salmon and Douglas Galasko
    Citation: Alzheimer's Research & Therapy 2021 13:121
    Content type: Research Published on:

  42. There is an urgent need for objective markers of Alzheimer’s disease (AD)-related cognitive impairment in people with Down syndrome (DS) to improve diagnosis, monitor disease progression, and assess response t...

    Authors: Alberto Lleó, Maria Carmona-Iragui, Laura Videla, Susana Fernández, Bessy Benejam, Jordi Pegueroles, Isabel Barroeta, Miren Altuna, Silvia Valldeneu, Mei-Fang Xiao, Desheng Xu, Raúl Núñez-Llaves, Marta Querol-Vilaseca, Sònia Sirisi, Alexandre Bejanin, M. Florencia Iulita…
    Citation: Alzheimer's Research & Therapy 2021 13:119
    Content type: Research Published on:

  43. Impaired self-awareness of memory function, a.k.a. anosognosia, is a common symptom in Alzheimer’s disease (AD); however, its pathological correlates remain unclear. Here, we investigated the impact of amyloid...

    Authors: Geoffroy Gagliardi, Madeline Kuppe, Cristina Lois, Bernard Hanseeuw and Patrizia Vannini
    Citation: Alzheimer's Research & Therapy 2021 13:118
    Content type: Research Published on:

  44. Genome-wide association studies (GWAS) have identified a number of genetic variants for Alzheimer’s disease (AD). However, most GWAS were conducted in individuals of European ancestry, and non-European populat...

    Authors: Hang-Rai Kim, Sang-Hyuk Jung, Jaeho Kim, Hyemin Jang, Sung Hoon Kang, Song Hwangbo, Jun Pyo Kim, So Yeon Kim, Beomsu Kim, Soyeon Kim, Jee Hyang Jeong, Soo Jin Yoon, Kyung Won Park, Eun-Joo Kim, Bora Yoon, Jae-Won Jang…
    Citation: Alzheimer's Research & Therapy 2021 13:117
    Content type: Research Published on:

  46. Alzheimer disease (AD) is the most common cause of dementia. Preclinical AD is the period during which early AD brain changes are present but cognitive symptoms have not yet manifest. The presence of AD brain ...

    Authors: Sayeh Bayat, Ganesh M. Babulal, Suzanne E. Schindler, Anne M. Fagan, John C. Morris, Alex Mihailidis and Catherine M. Roe
    Citation: Alzheimer's Research & Therapy 2021 13:115
    Content type: Research Published on:

  47. Neuronal hyperactivity related to β-amyloid (Aβ) is considered an early warning sign of Alzheimer disease (AD). Although increasing evidence supports this opinion, the underlying mechanisms are still unknown.

    Authors: Yang Li, Ke Zhu, Ning Li, Xiaotong Wang, Xuansheng Xiao, Linying Li, Lijuan Li, Ying He, Jinglan Zhang, Jiaoyang Wo, Yanqiu Cui, Haixia Huang, Jianliang Zhang, Wei Wang, Xiaomin Wang and Yan Zheng
    Citation: Alzheimer's Research & Therapy 2021 13:114
    Content type: Research Published on:

  48. Although few studies have shown that risk factors for Alzheimer’s disease (AD) are associated with cognitive decline in AD, not much is known whether the impact of risk factors differs between early-onset AD (...

    Authors: Jaeho Kim, Sook-Young Woo, Seonwoo Kim, Hyemin Jang, Junpyo Kim, Jisun Kim, Sung Hoon Kang, Duk L. Na, Juhee Chin, Liana G. Apostolova, Sang Won Seo and Hee Jin Kim
    Citation: Alzheimer's Research & Therapy 2021 13:113
    Content type: Research Published on:

  49. The described relationship between Alzheimer’s disease (AD) and type 2 diabetes (T2D) and the fact that AD has no succesful treatment has led to the study of antidiabetic drugs that may limit or slow down AD p...

    Authors: Maria Vargas-Soria, Maria Jose Carranza-Naval, Angel del Marco and Monica Garcia-Alloza
    Citation: Alzheimer's Research & Therapy 2021 13:112
    Content type: Mini review Published on:

  50. Challenges have been recognized in healthcare of patients with Alzheimer’s disease (AD) in the COVID-19 pandemic, given a high infection and mortality rate of COVID-19 in these patients. This situation urges t...

    Authors: Nian Xiong, Martin R. Schiller, Jingwen Li, Xiaowu Chen and Zhicheng Lin
    Citation: Alzheimer's Research & Therapy 2021 13:111
    Content type: Commentary Published on:
Submit manuscript

Follow

  • ISSN: 1758-9193 (electronic)

Alzheimer's Research & Therapy

ISSN: 1758-9193